The Xpert® Bladder Cancer Monitor, which was studied by D’Elia et al. in 2019 [53], analyzes five target mRNAs (ABL1, CRH, IGF2, UPK1B, and ANXA10) in voided and stabilized urine using quantitative real-time reverse transcription PCR. The gene discussed is ANXA10; the disease is urinary bladder carcinoma.